VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022. Following the positive recommendation from INESSS issued in October 2022, VRAYLAR ...

(RTTNews) - AbbVie (ABBV) announced that Alberta has added VRAYLAR® - cariprazine to its Health Drug Formulary, expanding public coverage for adults living with schizophrenia. This milestone ensures ...

(RTTNews) - AbbVie (ABBV) announced that Canada's Drug Agency has recommended that VRAYLAR be reimbursed with conditions, for the treatment of schizophrenia in adults. VRAYLAR, an atypical ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA has ...

This listing is a new step towards more equitable access to mental illness medication in Canada. As up to 90% of Canadians with serious mental illness are unemployed 3, public plan coverage is ...

(RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in ...

AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.

- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant ...